Galectin Therapeutics Inc (GALT) is a Healthcare · Biotechnology company listed on NASDAQ. Price $3.76 (+1.35%), Market cap $0.14B, 52-week low–high $1.24 ~ $6.51.
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension. It has a joint venture co-owned by SBH Sciences, Inc. to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011
Financial statements, price targets, institutional (13F) holdings and related news for Galectin Therapeutics Inc are updated in real time on BlackAll Trade.
Galectin Therapeutics Inc trades at $3.76 (+1.35%). Real-time quotes and charts are available on BlackAll Trade.
Galectin Therapeutics Inc has a market cap of about $0.14B.
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is bel